Clinical Trials Logo

Clinical Trial Summary

To compare the safety and efficacy of FFR (fractional flow reserve)-guided percutaneous coronary intervention (PCI) strategy with IVUS (intravascular ultrasound [IVUS])-guided PCI in patients with intermediate coronary stenosis.


Clinical Trial Description

1. Study overview This study is a prospective, open-label, randomized, multicenter trial to test the safety and efficacy of physiology- or imaging-guided PCI in patients with intermediate coronary stenosis.

The primary hypothesis is that FFR-guided strategy will show non-inferior rate of patients-oriented composite outcomes (POCO) at 24 months after randomization, compared with IVUS-guided strategy in patients with intermediate coronary stenosis.

2. Study population and sample size calculation

Sample Size Calculation Based on the event rates of previous trials, investigators predicted the rates of POCO at 24 months after PCI will be 10% in the FFR-guided arm, and 12% in the IVUS-guided arm.

- Primary endpoint: patient-oriented composite outcome (a composite of all-cause death, MI, any repeat revascularization) at 24 months after PCI

- Design: non-inferiority , delta = 2.5%

- Sampling ratio: FFR-guided strategy : IVUS-guided strategy = 1:1

- Type I error (α): One-sided 5%

- Accrual time : 2 years

- Total time : 4 years (accrual 2 year + follow-up 2 years)

- Assumption: POCO 10.0% vs. 12.0% in FFR or IVUS-guided strategy, respectively

- Statistical power (1- β): 90%

- Primary statistical method : Kaplan-Meier survival analysis with log-rank test

- Potential withdrawal rates : total 2%

- Stratification in Randomization: Presence of Diabetes Mellitus (600 patients (35%) will be Diabetic patients, with 300 patients in each group)

Based on the above assumption, 1,700 patients (850 patients in each group) will be enrolled in this study with consideration of withdrawal rates.

3. Research Materials and Indication for Revascularization For the FFR-guided strategy arm, a pressure-sensor wire system will be used and the criterion for revascularization is FFR ≤ 0.80. Hyperemia will be induced by intravenous infusion of adenosine (140ug/kg/min). For the IVUS-guided strategy arm, the criterion for revascularization is MLA ≤ 3mm2 or [3mm2 < MLA ≤ 4mm2 and plaque burden > 70%].

4. Funding This is an investigator-initiated study with grant support from Boston Scientific. Other than financial sponsorship, the company has no role in protocol development or the implementation, management, data collection, and analysis of this study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02673424
Study type Interventional
Source Seoul National University Hospital
Contact
Status Active, not recruiting
Phase N/A
Start date June 2016
Completion date January 2022

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02892903 - In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes? N/A
Not yet recruiting NCT02871622 - BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM N/A
Completed NCT02252406 - Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome Phase 4
Not yet recruiting NCT02550301 - Does Mean Platelet Volume Change With Clopidogrel N/A
Active, not recruiting NCT02244853 - Heart Rate and Cardiovascular Diseases Prognosis in People With Stable Coronary Artery Disease N/A
Completed NCT01826552 - Comparison of the Angiographic Result of the Orsiro Hybrid Stent With Resolute Integrity Stent Phase 4
Not yet recruiting NCT01162902 - Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation Phase 4
Completed NCT02126150 - United Coronary Biobanks N/A
Completed NCT01769079 - Clinical Impact of the Withdrawal of Nitrate in Patients With Stable Angina Phase 4
Completed NCT01328470 - Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Chronic Kidney Disease Phase 4
Unknown status NCT00751491 - Clopidogrel Versus Adenosin in Non Urgent Percutaneous Coronary Intervention (PCI) Phase 3
Completed NCT00263263 - RRISC Study: Reduction of Restenosis In Saphenous Vein Grafts With Cypher Sirolimus-Eluting Stent. Phase 2
Recruiting NCT04929496 - Physiology as Guidance to Evaluate the Direct Impact of Coronary Lesion Treatment: The PREDICT Study N/A
Completed NCT03103620 - Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry
Recruiting NCT05459051 - Finding the Invasive Haemodynamic Threshold for Symptom Relief in Stable Angina
Not yet recruiting NCT04403048 - Drug Coated Balloon for Side Branch Treatment vs. Conventional Approach in True Bifurcation Coronary Disease: PRO-DAVID N/A
Completed NCT01974492 - Comparison of Saphenous Vein Graft Harvested From Upper Versus Lower Leg in Coronary Artery Bypass Grafting N/A
Completed NCT02120859 - Optical Coherence Tomography to Investigate FFR-Guided DEB-only Elective Coronary Angioplasty Phase 4
Completed NCT01990924 - Low Rate Fluoroscopy to Reduce Radiation Dose During Coronary Angiography and Intervention N/A
Terminated NCT01394848 - Safety and Efficacy Study of Endothelial Progenitor Cell Capture Stent With 1 Months Dual Antiplatelet Therapy Phase 4